IOVANCE BIOTHERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $1.07 million for the 6-month period ending 2016-06-30, per its 10-Q filed 2016-08-09.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2016-08-09
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2016-06-30 was $772.00K, a 21.11% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2016-03-31 was $296.00K, a 34.29% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2015-12-31 was -$1.55M.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2015-09-30 was $465.13K.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2015 was $0.00.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2016-06-30 | $772.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $1.07M 10-Q · filed 2016-08-09 | -$485.00K derived: sum of 3 quarters · filed 2016-08-09 | -$19.87K derived: sum of 4 quarters · filed 2016-08-09 |
| 2016-03-31 | $296.00K 10-Q · filed 2016-05-09 | -$1.26M derived: sum of 2 quarters · filed 2016-05-09 | -$791.87K derived: sum of 3 quarters · filed 2016-05-09 | -$154.44K derived: sum of 4 quarters · filed 2016-05-09 |
| 2015-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$1.09M derived: sum of 2 quarters · filed 2016-03-11 | -$450.44K derived: sum of 3 quarters · filed 2016-03-11 | $0.00 10-K · filed 2016-03-11 |
| 2015-09-30 | $465.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $1.10M derived: sum of 2 quarters · filed 2015-11-06 | $1.55M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $637.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $1.09M 10-Q · filed 2015-08-10 | ||
| 2015-03-31 | $450.44K 10-Q · filed 2015-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |